The Guidelines of Material Design and Process Control on Hybrid Fiber Metal Laminate for Aircraft Structures

Fiber metal laminate (FML) is a hybrid material system that consists of thin metal sheets bonded into a laminate with intermediate thin fiber reinforced composite layers. The aerospace industry has recently increased their use of FMLs due to the considerable weight reduction and consequent benefits for critical load-carrying locations in commercial aircraft, such as upper fuselage skin panels. All FML materials and their processes should be qualified through enough tests and fabrication trials to demonstrate reproducible and reliable design criteria. In particular, proper surface treatment technologies are prerequisite for achieving long-term service capability through the adhesive bonding process. This chapter introduces a brief overview of design concept, material properties and process control methodologies to provide detailed background information with engineering practices and to help ensure stringent quality controls and substantiation of structure integrity. The guidelines and information found in this chapter are meant to be a documentation of current knowledge and an application of sound engineering principles to the FML part development for aerospace usage

2.45 GHz Active Isolator based on asymmetric coupler

An active isolator achieving both high isolation and low insertion loss at 2.45 GHz is proposed. The isolator is based on an asymmetric coupler and is designed to leverage the gain and reverse isolation of an amplifier and coupling coefficients between the input and output of the coupler. The insertion loss and isolation of the isolator are enhanced by using the coefficients, and the power level with optimal isolation can be determined for a target specification. The asymmetric coupler increases the power handling capability of the proposed isolator that has a low coupling coefficient and achieves highly efficient isolation with a high coupling coefficient. Electromagnetic-circuit co-simulation results show that the proposed isolator with operation stability has ≥40 dB isolation and <1 dB insertion loss for input power between 0−8 dBm

Refining Historical earthquake Data Through Modeling and Scale Model Tests

This study was performed for the reevaluation of historical earthquake records which occurred in Korea through tests and numerical analyses. For the scale model tests, static and cyclic lateral load tests on wooden frames that constitute a Korean ancient commoner’s house were conducted. Full-scale models of two types of frames were used for testing. Two 1:4 scale models were tested for rock and soil foundation conditions. Scaled real earthquake time histories were inputted for the tests. The peak ground acceleration (PGA) at the collapse of the house at the soil site was 0.25g, whereas PGA for moderate damage at the rock site was 0.6g. The intensity of major historical earthquake records related with house collapses was reevaluated based on the results of these scale mode1 tests. The magnitudes of historical earthquake records related with house collapses were estimated considering the magnitude, epicentral distance, soil condition and aging of the house. Eighteen artificial time histories for magnitudes 6-8, epicentral distances 5 km - 350 km and hard and soft soil condition were generated. The aging effects of the house was modeled as the lateral loading capacity of wooden frames represented by hysteretic stiffness decreased linearly with time

A novel de novo mutation in the serine-threonine kinase STK11 gene in a Korean patient with Peutz-Jeghers syndrome

BACKGROUND: Peutz-Jeghers syndrome (PJS) is an unusual autosomal dominant disorder characterized by mucocutaneous pigmentation and multiple gastrointestinal hamartomatous polyps. Patients with PJS are at an increased risk of developing multi-organ cancer, most frequently those involving the gastrointestinal tract. Germline mutation of the STK11 gene, which encodes a serine-threonine kinase, is responsible for PJS. METHODS: Using DNA samples obtained from the patient and his family members, we sequenced nine exons and flanking intron regions of the STK11 gene using polymerase chain reaction (PCR) and direct sequencing. RESULTS: Sequencing of the STK11 gene in the proband of the family revealed a novel 1-base pair deletion of guanine (G) in exon 6 (c.826delG; Gly276AlafsX11). This mutation resulted in a premature termination at codon 286, predicting a partial loss of the kinase domain and complete loss of the C-terminal domain. We did not observe this mutation in both parents of the PJS patient. Therefore, it is considered a novel de novo mutation. CONCLUSION: The results presented herein enlarge the spectrum of mutations of the STK11 gene by identifying a novel de novo mutation in a PJS patient and further support the hypothesis that STK11 mutations are disease-causing mutations for PJS with or without a positive family history

Favored serum albumin level and ICF volume after use of 1.1% aminoacid based peritoneal dialysis(PD) solution

Aminoacid based PD solution (AAD) has been shown to induce positive nitrogen balance and improve nutritional markers of malnourished patients. But its effcets on body fluid composition and various nutritional markers are contradictory. Nutritional markers may influenced by patient's ECF volume status. So we evaluate effects of AAD on nutritional markers and body composition by analysis using multi-frequency bioimpedance analyzer. 35 PD patients(>6months duration of CAPD) were prospectively randomized to 17 AAD(Nutrineal, one time use/day) and 18 GD group(keep their glucose based PD solution). After 3 months follow up, AAD group showed marginally increased body weight and fat mass, decreased ECF volume(12.45±0.54Lvs 12.10±0.57L, p=0.06), no changed ICF volume(22.2±0.9Lvs 22.3±0.9L, p>0.05) and marginally increased drainage volume(8.77±0.76Lvs 9.12±0.83L, p=0.09). AAD group also showed favored several markers include nPCR(1.59±0.07vs 1.98±0.08, p=0.00), BUN and albumin level (3.54±0.11 vs 3.74±0.11, p=0.02). Although serum albumin level was increased, correction with ECF volume(albumin level X ECF volume) makes it no difference (43.45±2.13vs 44.80±2.28, p=0.14). Furthermore △albumin vs △ECF showed negative correlation pattern(r=-0.46, p=0.07) that means serum albumin change was influenced by ECF volume change. In conclusion, AAD treatment improved markers of better nutritional status. However the change in serum albumin level was influenced by patient's ECF volume status, which can partially explain contradictory effect of aminoacid based PD solution on serum albumin level

The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1

Gemcitabine is used to treat several cancers including lung cancer. However, tumor cells often escape gemcitabine-induced cell death via various mechanisms, which include modulating bcl-2 family members and NF-κB activation. We previously reported that the C-terminal region of Bfl-1 fused with GFP (BC) is sufficient to induce apoptosis in 293T cells. In the present study, we investigated the anti-tumor effect of combined BC gene therapy and gemcitabine chemotherapy in vitro and in vivo using non-small cell lung cancer cell lines and a xenograft model. Cell lines were resistant to low dose gemcitabine (4-40 ng/ml), which induced NF-κB activation and concomitant up-regulation of Bfl-1 (an NF-κB-regulated anti-apoptotic protein). BC induced the apoptosis of A549 and H157 cells with caspase-3 activation. Furthermore, co-treatment with BC and low dose gemcitabine synergistically and efficiently induced mitochondria-mediated apoptosis in these cells. When administered alone or with low dose gemcitabine, BC suppressed NF-κB activity, inhibited the nuclear translocation of p65/relA, and down-regulated Bfl-1 expression. Furthermore, direct suppression of Bfl-1 by RNA interference sensitized cells to gemcitabine-induced cell death, suggesting that Bfl-1 importantly regulates lung cancer cell sensitivity to gemcitabine. BC and gemcitabine co-treatment also showed a strong anti-tumor effect in a nude mouse/A549 xenograft model. These results suggest that lung cancer cells become resistant to gemcitabine via NF-κB activation and the subsequent overexpression of Bfl-1, and that BC, which has both pro-apoptotic and NF-κB inhibitory effects, could be harnessed as a gene therapy to complement gemcitabine chemotherapy in non-small cell lung cancer